Concord Biotech Limited Stock Price Today (NSE: CONCORDBIO)
Fundamental Score
Concord Biotech Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Concord Biotech Limited share price today is ₹1453.80, down 1.30% on NSE/BSE as of 16 September 2026. Concord Biotech Limited (CONCORDBIO) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹15.21K (Cr). The 52-week high for CONCORDBIO share price is ₹1704.00 and the 52-week low is ₹987.00. At a P/E ratio of 55.72x, CONCORDBIO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.63% and a debt-to-equity ratio of 0.00.
Concord Biotech Limited Share Price Chart — NSE/BSE Historical Performance
Concord Biotech Limited share price chart: 3.63% return over the past month. 52-week high ₹1704.00, 52-week low ₹987.00.
Concord Biotech Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1470.10 | ₹1484.20 | ₹1428.10 | ₹1453.80 | 1.06L (Cr) | |
| ₹1513.60 | ₹1527.10 | ₹1467.00 | ₹1473.00 | 97.03K (Cr) | |
| ₹1439.60 | ₹1529.00 | ₹1426.90 | ₹1505.70 | 3.73L (Cr) | |
| ₹1472.20 | ₹1472.20 | ₹1432.00 | ₹1452.80 | 1.06L (Cr) | |
| ₹1474.00 | ₹1479.80 | ₹1447.60 | ₹1464.50 | 1.41L (Cr) | |
| ₹1443.20 | ₹1492.00 | ₹1437.80 | ₹1470.50 | 2.02L (Cr) | |
| ₹1417.10 | ₹1456.10 | ₹1417.00 | ₹1443.20 | 62.12K (Cr) | |
| ₹1450.00 | ₹1450.40 | ₹1411.60 | ₹1417.10 | 59.14K (Cr) | |
| ₹1450.90 | ₹1461.80 | ₹1435.00 | ₹1447.70 | 69.96K (Cr) | |
| ₹1485.00 | ₹1492.80 | ₹1440.90 | ₹1444.80 | 90.96K (Cr) |
Concord Biotech Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1458.90 | ₹1529.00 | ₹1411.60 | ₹1453.80 | -0.35% | |
| ₹1444.40 | ₹1615.00 | ₹1356.40 | ₹1446.10 | +0.12% | |
| ₹1297.40 | ₹1429.40 | ₹1238.00 | ₹1420.80 | +9.51% | |
| ₹1047.80 | ₹1407.90 | ₹1022.20 | ₹1280.20 | +22.18% | |
| ₹1158.90 | ₹1234.20 | ₹1040.30 | ₹1051.20 | -9.29% | |
| ₹1065.00 | ₹1164.10 | ₹987.00 | ₹1142.00 | +7.23% | |
| ₹1196.00 | ₹1230.00 | ₹990.60 | ₹1018.40 | -14.85% | |
| ₹1142.60 | ₹1385.00 | ₹1068.60 | ₹1220.60 | +6.83% | |
| ₹1345.60 | ₹1455.00 | ₹1155.70 | ₹1175.20 | -12.66% | |
| ₹1417.60 | ₹1445.10 | ₹1314.90 | ₹1345.60 | -5.08% | |
| ₹1443.80 | ₹1513.00 | ₹1383.00 | ₹1417.60 | -1.81% | |
| ₹1647.70 | ₹1667.60 | ₹1425.20 | ₹1443.80 | -12.37% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Concord Biotech Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Concord Biotech Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CONCORDBIO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (17.47%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (42.06%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (32.84%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (26.23%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (1207.70x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 6.17)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹637.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 55.72x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (8.39x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-37.52% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.92% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Concord Biotech Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Concord Biotech Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Concord Biotech LimitedConcord Biotech...Selected✓ CONCORDBIO • 543960 | 42.5/100 | ₹1453.80₹1454 | ₹15209.07₹15209.07 | 55.72Average 55.7 Average | 13.63%Average 13.63% Average | 17.47%Good 17.47% Good | 0.00Excellent 0.0 Excellent | 0.92%Average 0.92% Average | 11.33%Good 11.33% Good | 0.56% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Concord Biotech Limited PE Ratio History
Historical price-to-earnings ratio for CONCORDBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹35.52 | ₹1345.60 | 37.9x |
| FY 2024 | ₹29.45 | ₹2210.75 | 75.1x |
| FY 2023 | ₹22.95 | ₹1471.80 | 64.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Concord Biotech Limited Dividend History
Annual cash dividends paid by CONCORDBIO — dividend yield 0.56%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹91.54 Cr |
| FY 2024 | ₹71.45 Cr |
| FY 2023 | ₹53.56 Cr |
| FY 2022 | ₹70.52 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Concord Biotech Limited Quarterly Performance
Latest quarterly metrics for CONCORDBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
26.23%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
32.84%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.33%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.92%
Compounded annual net profit growth over 5 years
Concord Biotech Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CONCORDBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Concord Biotech Limited Financial Statements
Annual income statement, balance sheet and cash flow for Concord Biotech Limited (CONCORDBIO) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Concord Biotech Limited
About CONCORDBIO (Concord Biotech Limited)
Concord Biotech Ltd is a pioneering force in the realm of biopharmaceutical innovation, dedicated to pushing the boundaries of drug development and manufacturing. At its core, the ...company is driven by a relentless pursuit of scientific excellence, meticulously crafting novel pharmaceutical solutions for a diverse range of global healthcare needs. With a steadfast commitment to research and development, Concord Biotech navigates the complexities of modern medicine, striving to deliver life-enhancing therapies that address critical medical challenges. Their unwavering dedication to quality and innovation positions them as a key player in the pharmaceutical landscape, constantly evolving to meet the ever-changing demands of the industry. Concord Biotech's expertise shines through in its specialized focus on fermentation-derived active pharmaceutical ingredients (APIs), particularly within the crucial therapeutic areas of immunosuppression, oncology, and infection control. By harnessing the power of microbial fermentation, the company meticulously cultivates and refines potent APIs, serving as the building blocks for transformative medications. Concord Biotech's deep understanding of fermentation processes allows it to develop and manufacture APIs with high precision and efficacy, ultimately impacting the lives of patients worldwide. This specialized focus, combined with rigorous quality control measures, solidifies Concord Biotech's reputation as a trusted provider of vital pharmaceutical components. Among its notable offerings, Concord Biotech boasts a portfolio of critical immunosuppressant APIs, playing a vital role in transplant medicine and the management of autoimmune disorders. These APIs, including tacrolimus, mycophenolate, cyclosporine, and sirolimus, are essential in preventing organ rejection and suppressing the immune system in various conditions. By ensuring a reliable supply of these crucial components, Concord Biotech actively contributes to the success of life-saving transplant procedures and the improved quality of life for patients battling immune-related diseases. This commitment to providing high-quality immunosuppressant APIs underscores Concord Biotech's dedication to meeting critical healthcare needs on a global scale.
Company Details
Key Leadership
CONCORDBIO Share Price: Frequently Asked Questions
What is the current share price of Concord Biotech Limited?
Concord Biotech Limited (CONCORDBIO) trades at ₹1453.80 on NSE and BSE. Market cap ₹15.21K (Cr). Educational data only.
What is the P/E ratio of Concord Biotech Limited?
Concord Biotech Limited has a P/E of 55.72x vs industry average 34.89x.
What is the Bull Run score for Concord Biotech Limited?
Concord Biotech Limited has a Bull Run score of 42.5/100 based on 25+ financial parameters.
Does Concord Biotech Limited pay dividends?
Concord Biotech Limited has a dividend yield of 0.56%. Past dividends don't guarantee future payments.
What is the ROE of Concord Biotech Limited?
Concord Biotech Limited has ROE of 13.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Concord Biotech Limited?
Concord Biotech Limited has debt-to-equity of 0.00.
Is Concord Biotech Limited a good investment?
Bull Run gives Concord Biotech Limited a score of 42.5/100. This is not investment advice — consult a SEBI-registered advisor.